Aortic stenosis (AS) is the most common valvular heart disease in developed countries, 1 affecting up to 10% of the population in the eighth decade of life 2 and generally associated with poor survival in moderate or severe stages. 3 The pathology of AS is described as a progressive fibro-calcific remodeling resulting in thickened valve leaflets eventually leading to obstruction of cardiac outflow. 4 This remodeling is a result of genetic predispositions causing complex structural anomalies such as bicuspid valve, metabolic syndromes with lipoprotein deposition and oxidation, chronic inflammation, and osteoblastic transition of interstitial cells in valvular tissue with active calcification of valve leaflets. 4 The biological process underlying the development of AS remains an area of intensive investigation-a cursory search of the literature revealed more than 20 papers examining potential genetic pathways impacting AS published within the last 5 years alone (Table 1) . Nevertheless, there are currently no available preventative therapies for AS! In this article, Khan and colleagues 26 present work which delineates the role of urotensin II, urotensin-related peptide, and the urotensin receptor in the pathophysiology of calcified AS. Vasoactive mediators in this family play a role in cardiovascular diseases such as atherosclerosis and heart failure. [27] [28] [29] Tissue samples from 36 calcified and 25 normal aortic valves were harvested and used to isolate human aortic valve interstitial cells. Further testing revealed elevated mRNA expression of urotensin II, urotensin-related peptide, and urotensin receptor (urotensin receptor family) in calcified valves compared with normal valvular tissue through real-time polymerase chain reaction. These findings demonstrate upregulation of genetic pathways related to increased mineralization and cell proliferation after treatment of human aortic valve interstitial cells with the urotensin receptor family. Thus, the potential impact of the urotensin receptor family on the pathophysiology of AS was demonstrated.
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The rise of transcatheter valve therapies has revolutionized the treatment of AS over the last decade. We anticipate Cadherin-11
SOX9
Bone morphogenetic protein-2 (BMP-2) and Transforming growth factor beta 1 (TGF-b1)
the next sea-change in the management of aortic valve disease will focus on the prevention of AS, rather than treatment at its end stage. The work of Khan and colleagues has added another puzzle piece to a growing pile of genetic pathways implicated in the pathogenesis of AS. Future work should focus on delineating the interplay between these many pathways-putting the puzzle pieces together-so that targeted therapies can be developed for the prevention of AS. 
